Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ipsen Pharma

< Previous 1 2 Next >
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
From Ipsen Pharma
Via GlobeNewswire
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
Ipsen updates on QM-1114 regulatory process
From Ipsen Pharma
Via GlobeNewswire
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
From Ipsen Pharma
Via GlobeNewswire
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Ipsen Pharma
Via GlobeNewswire
US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
From Ipsen Pharma
Via GlobeNewswire
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
From Ipsen Pharma
Via GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
From Ipsen Pharma
Via GlobeNewswire
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
From Ipsen Pharma
Via GlobeNewswire
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
From Ipsen Pharma
Via GlobeNewswire
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
From Ipsen Pharma
Via GlobeNewswire
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
From Ipsen Pharma
Via GlobeNewswire
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
From Ipsen Pharma
Via GlobeNewswire
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
From Ipsen Pharma
Via GlobeNewswire
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
From Ipsen Pharma
Via GlobeNewswire
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
From Ipsen Pharma
Via GlobeNewswire
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
From Ipsen Pharma
Via GlobeNewswire
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
From Ipsen Pharma
Via GlobeNewswire
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
From Ipsen Pharma
Via GlobeNewswire
Ipsen presents strong full-year 2022 results and guidance for 2023
From Ipsen Pharma
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.